(function(){ var content_array=["
*<\/i>歐狄沃<\/i>[7]<\/span><\/sup>于2014年7月獲批成為全球首個PD-1抑制劑,目前已在66個國家和地區獲批共11個瘤種,涵蓋肺癌、頭頸癌、胃癌、食管癌、肝癌、腎癌、結直腸癌、尿路上皮癌、黑色素瘤、霍奇金淋巴瘤、胸膜腫瘤,惠及超過590,000名全球患者。<\/p> \n 歐狄沃<\/i>是中國首個獲批上市的免疫腫瘤藥物,目前在中國獲批共3項適應癥,除下列以外其他適應證尚未獲批:<\/p> \n 1) 用于治療表皮生長因子受體(EGFR)基因突變陰性和間變性淋巴瘤激酶(ALK)陰性、既往接受過含鉑方案化療后疾病進展或不可耐受的局部晚期或轉移性非小細胞肺癌(NSCLC)的成人患者; 歐狄沃<\/i>是唯一由諾貝爾生理學或醫學獎得主直接參與開發的PD-1抑制劑 。百時美施貴寶擁有本庶佑博士的PD-1專利獨家使用權。<\/p> \n [1] Opdivo Prescribing Information. Opdivo U.S. Product Information. Last updated: April 2021. Princeton, NJ: Bristol-Myers Squibb Company.<\/span><\/p> <\/td> \n <\/tr> \n [2] Moehler M, Shitara K, Garrido M, et al. Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer\/gastroesophageal junction cancer\/esophageal adenocarcinoma: first results of the CheckMate 649 study. Late-breaker presented at: 2020 European Society for Medical Oncology (ESMO) Virtual Congress. September 19-21, 2020.<\/span><\/p> <\/td> \n <\/tr> \n [3]Samson P and Lockhart AC. Biologic therapy in esophageal and gastric malignancies: current therapies and future directions. J Gastrointest Oncol. 2017;8(3):418-429.<\/span><\/p> <\/td> \n <\/tr> \n [4] Murphy AG, Lynch D and Kelly RJ. State of the art management of metastatic gastroesophageal cancer. Ann Transl Med. 2015;3(16):236.<\/span><\/p> <\/td> \n <\/tr> \n [5] Ai D, Zhu H, Ren W, et al. Patterns of distant organ metastases in esophageal cancer: a population-based study. J Thorac Dis. 2017;9(9):3023-3030.<\/span><\/p> <\/td> \n <\/tr> \n [6] Nagaraja AK, Kikuchi O and Bass AJ. Genomics and targeted therapies in gastroesophageal adenocarcinoma. Cancer Discov. 2019;9(12):1656-1672.<\/span><\/p> <\/td> \n <\/tr> \n [7] 注:歐狄沃<\/i>為基礎的免疫單藥治療及免疫聯合治療方案<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n <\/p>"];
$("#dvExtra").html(content_array[0]);})();
2) 用于接受含鉑類方案治療期間或之后出現疾病進展且腫瘤PD-L1表達陽性(表達PD-L1的腫瘤細胞≥1%)的復發性或轉移性頭頸部鱗狀細胞癌(SCCHN)患者;
3) 用于治療既往接受過兩種或兩種以上全身性治療方案的晚期或復發性胃或胃食管連接部腺癌患者。<\/p> \n \n \n
\n \n \n \n \n \n \n